Citations

Clear

1820 citation(s) found for "Israel, E".

Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial
Krueger, James G. , Mukhopadhyay, Sutirtha, Gao, Heli , Ranganathan, Usha, Ivanoff, Nathalie, Daly, Ana C Hernandez, Zouboulis, Christos C , Alavi, Afsáneh , Prens, Errol P. , Kimball, Alexa B. , Frew, John W. , Mukhopadhyay, Sutirtha, Ranganathan, Usha, Daly, Ana Cristina Hernandez , Zouboulis, Christos C.

Mayo Clinic

British Journal of Dermatology | April 5, 2024 | Volume: 191 | Issue: 4 | Pages: 508-518

10.1093/bjd/ljae144 | PMID 38576350 Get It

Abstract Background Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a considerable disease burden. Existing treatment options are limited and often suboptimal; a high unmet need exists for effective targeted therapies. Objectives To explore the effects of spesolimab treatment in patients with HS. Methods This randomized double-blind placebo-controlled proof-of-clinical-concept (PoCC) study was conducted at 25 centres across 12 countries from 3 May 2021 to 21 April 2022. Patients had moderate-to-severe HS for ≥ 1 year before enrolment. Patients were randomized (2 : 1) to receive a loading dose of 3600-mg intravenous spesolimab (1200 mg at weeks 0, 1 and 2) or matching placebo, followed by maintenance with either 1200-mg subcutaneous spesolimab every 2 weeks from weeks 4 to 10 or matching placebo. The primary endpoint was the percentage change from baseline in total abscess and inflammatory nodule (AN) count at week 12. Secondary endpoints were the absolute change from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4), percentage change from baseline in draining tunnel (dT) count, the proportion of patients achieving a dT count of 0, absolute change from baseline in the revised Hidradenitis Suppurativa Area and Severity Index (HASI-R), the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR50), the proportion of patients with ≥ 1 flare (all at week 12) and patient-reported outcomes. Results In this completed trial, randomized patients (n = 52) received spesolimab (n = 35) or placebo (n = 17). The difference vs. placebo in least squares mean is reported. At week 12, the percentage change in total AN count was similar between treatment arms: –4.1% [95% confidence interval (CI) –31.7 to 23.4]. There was greater numerical improvement in the spesolimab arm, as measured by IHS4 (13.9, 95% CI –25.6 to –2.3); percentage change from baseline in dT count (–96.6%, 95% CI –154.5 to –38.8); and the proportion of patients achieving a dT count of 0 (18.3%, 95% CI –7.9 to 37.5). Spesolimab treatment also improved HASI-R and HiSCR50 vs. placebo. Spesolimab demonstrated a favourable safety profile, similar to that observed in trials in other diseases. Conclusions This exploratory PoCC study supports the development of spesolimab as a new therapeutic option in HS.
US Liver Transplant Outcomes After Normothermic Regional Perfusion vs Standard Super Rapid Recovery
Sellers, Marty T., Abt, Peter L. , Merani, Shaheed , Alebrahim, Musab, Baskin, Roy H., Cederquist, K., Huerter, Benjamin G., Kautzman, Lori, Langnas, Alan N. , Manzi, João , Nassar, Ahmed , Neidlinger, Nikole , Nydam, Trevor L. , Siddiqui, Farjad , Suah, Ashley, Taj, Raeda , Testa, Giuliano , Vianna, Rodrigo , Vyas, Frederick, Montenovo, Martin I. , Taner, C. Burcin , Brubaker, Aleah L. , Croome, Kristopher P. , Wall, Anji , Abreu, Phillipe , Bohorquez, Humberto E. , Cannon, Robert M. , Edwards, John G. , Hobeika, Mark J. , Lee, David D. , Schnickel, Gabriel T

Mayo Clinic

JAMA Surgery | April 3, 2024 | Volume: 159 | Issue: 6 | Pages: 677

10.1001/jamasurg.2024.0520 | PMID 38568597 Get It

Importance Normothermic regional perfusion (NRP) is an emerging recovery modality for transplantable allografts from controlled donation after circulatory death (cDCD) donors. In the US, only 11.4% of liver recipients who are transplanted from a deceased donor receive a cDCD liver. NRP has the potential to safely expand the US donor pool with improved transplant outcomes as compared with standard super rapid recovery (SRR). Objective To assess outcomes of US liver transplants using controlled donation after circulatory death livers recovered with normothermic regional perfusion vs standard super rapid recovery. Design, Setting, and Participants This was a retrospective, observational cohort study comparing liver transplant outcomes from cDCD donors recovered by NRP vs SRR. Outcomes of cDCD liver transplant from January 2017 to May 2023 were collated from 17 US transplant centers and included livers recovered by SRR and NRP (thoracoabdominal NRP [TA-NRP] and abdominal NRP [A-NRP]). Seven transplant centers used NRP, allowing for liver allografts to be transplanted at 17 centers; 10 centers imported livers recovered via NRP from other centers. Exposures cDCD livers were recovered by either NRP or SRR. Main Outcomes and Measures The primary outcome was ischemic cholangiopathy (IC). Secondary end points included primary nonfunction (PNF), early allograft dysfunction (EAD), biliary anastomotic strictures, posttransplant length of stay (LOS), and patient and graft survival. Results A total of 242 cDCD livers were included in this study: 136 recovered by SRR and 106 recovered by NRP (TA-NRP, 79 and A-NRP, 27). Median (IQR) NRP and SRR donor age was 30.5 (22-44) years and 36 (27-49) years, respectively. Median (IQR) posttransplant LOS was significantly shorter in the NRP cohort (7 [5-11] days vs 10 [7-16] days; P < .001). PNF occurred only in the SRR allografts group (n = 2). EAD was more common in the SRR cohort (123 of 136 [56.1%] vs 77 of 106 [36.4%]; P = .007). Biliary anastomotic strictures were increased 2.8-fold in SRR recipients (7 of 105 [6.7%] vs 30 of 134 [22.4%]; P = .001). Only SRR recipients had IC (0 vs 12 of 133 [9.0%]; P = .002); IC-free survival by Kaplan-Meier was significantly improved in NRP recipients. Patient and graft survival were comparable between cohorts. Conclusion and Relevance There was comparable patient and graft survival in liver transplant recipients of cDCD donors recovered by NRP vs SRR, with reduced rates of IC, biliary complications, and EAD in NRP recipients. The feasibility of A-NRP and TA-NRP implementation across multiple US transplant centers supports increasing adoption of NRP to improve organ use, access to transplant, and risk of wait-list mortality.
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi
Tapper, Elliot B. , Shah, Rajesh P. , Emamaullee, Juliet , Poston, Jacqueline N. , Soto, Robin J., Pillai, Anjana , Reyner, Karina, Mehta, Shivang , Ghabril, Marwan , Morgan, Timothy R. , Caldwell, Stephen H. , Ghabril, Marwan S , Warner, Matthew A. , Dunbar, Nancy M. , Sholzberg, Michelle , Sarwar, Ammar

Mayo Clinic

Hepatology | April 1, 2024 | Volume: 80 | Issue: 2 | Pages: 488-499

10.1097/hep.0000000000000856 | PMID 38557474 Get It

Patients with cirrhosis have abnormal coagulation indices such as a high international normalized ratio and low platelet count, but these do not correlate well with periprocedural bleeding risk. We sought to develop a consensus among the multiple stakeholders in cirrhosis care to inform process measures that can help improve the quality of the periprocedural management of coagulopathy in cirrhosis. We identified candidate process measures for periprocedural coagulopathy management in multiple contexts relating to the performance of paracentesis and upper endoscopy. An 11-member panel with content expertise was convened. It included nominees from professional societies for interventional radiology, transfusion medicine, and anesthesia as well as representatives from hematology, emergency medicine, transplant surgery, and community practice. Each measure was evaluated for agreement using a modified Delphi approach (3 rounds of rating) to define the final set of measures. Out of 286 possible measures, 33 measures made the final set. International normalized ratio testing was not required for diagnostic or therapeutic paracentesis as well as diagnostic endoscopy. Plasma transfusion should be avoided for all paracenteses and diagnostic endoscopy. No consensus was achieved for these items in therapeutic intent or emergent endoscopy. The risks of prophylactic platelet transfusions exceed their benefits for outpatient diagnostic paracentesis and diagnostic endosopies. For the other procedures examined, the risks outweigh benefits when platelet count is >20,000/mm 3 . It is uncertain whether risks outweigh benefits below 20,000/mm 3 in other contexts. No consensus was achieved on whether it was permissible to continue or stop systemic anticoagulation. Continuous aspirin was permissible for each procedure. Clopidogrel was permissible for diagnostic and therapeutic paracentesis and diagnostic endoscopy. We found many areas of consensus that may serve as a foundation for a common set of practice metrics for the periprocedural management of coagulopathy in cirrhosis.
Prognostic impact of combined non-severe aortic stenosis and mitral regurgitation on clinical outcomes: a single-centre retrospective study
Granot, Yoav , Sapir, Orly Ran , Laufer‐Perl, Michal , Viskin, Dana , Banai, Shmuel , Topilsky, Yan , Havakuk, Ofer , Topilsky, Yan , Havakuk, Ofer

Mayo Clinic

BMJ Open | March 29, 2024 | Volume: 14 | Issue: 3 | Pages: e080914

10.1136/bmjopen-2023-080914 | PMID 38553077 Get It

Objectives Though the concomitant occurrence of non-severe aortic stenosis (AS) and mitral regurgitation (MR) is highly prevalent, there are limited data to guide clinical decision-making in this condition. Here, we attempt to determine an aortic valve area (AVA) cut-off value associated with worse clinical outcomes in patients with combined non-severe AS and MR. Methods Single-centre, retrospective analysis of consecutive patients who underwent echocardiography examination between 2010 and 2021 with evidence of combined non-severe AS and MR. We excluded patients with ≥moderate aortic valve regurgitation or mitral stenosis, as well as patients who underwent any aortic or mitral intervention either prior or following our assessment (n=372). Results The final cohort consisted of 2933 patients with non-severe AS, 506 of them with >mild MR. Patients with both pathologies had lower cardiac output and worse diastolic function. Patients with an AVA ≤1.35 cm² in the presence of >mild MR had the highest rates of heart failure (HF) hospitalisations (HR 3.1, IQR 2.4–4, p<0.001) or mortality (HR 2, IQR 1.8–2.4, p<0.001), which remained significant after adjusting for clinical and echocardiographic parameters. Conclusion Patients with combined non-severe AS and MR have a higher rate of HF hospitalisations and mortality. An AVA≤1.35 cm² in the presence of >mild MR is associated with worse clinical outcomes.
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen
Abramson, Jeremy S, Solomon, Scott R. , Arnason, Jon , Johnston, Patrick B., Glaß, Bertram , Bachanová, Veronika , Mielke, Stephan , Mutsaers, Pim , Hernandez‐Ilizaliturri, Francisco J. , Lunning, Matthew A. , Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro , Kamdar, Manali , Bachanova, Veronika , Kamdar, Manali , Mielke, Stephan , Abramson, Jeremy S, Johnston, Patrick B. , Ibrahimi, Sami , Izutsu, Koji , Morschhauser, Franck , Ogasawara, Ken

Mayo Clinic

Future Oncology | March 28, 2024 | Volume: 20 | Issue: 21 | Pages: 1455-1465

10.2217/fon-2023-0898 | PMID 38547003 Get It

Rh immune globulin immunoprophylaxis after RhD‐positive red cell exposure in RhD‐negative patients via transfusion: A survey of practices
Stephens, Laura D. , Shmookler, Aaron , O’Brien, Kerry L., Hermelin, Daniela , Bakhtary, Sara , AlMozain, Nour , Lu, Wen , Stephens, Laura , Shmookler, Aaron , O'Brien, Kerry , Karp, Julie Katz , Hermelin, Daniela , Bakhtary, Sara , Fung, Mark K , Almozain, Nour , George, Melissa

Mayo Clinic

Transfusion | March 27, 2024 | Volume: 64 | Issue: 5 | Pages: 839-845

10.1111/trf.17812 | PMID 38534065 Get It

AbstractBackgroundCurrent Association for the Advancement of Blood & Biotherapies (AABB) standards require transfusion services to have a policy on Rh immune globulin (RhIG) immunoprophylaxis for when RhD‐negative patients are exposed to RhD‐positive red cells. This is a survey of AABB‐accredited transfusion services in the United States (US) regarding institutional policies and practices on RhIG immunoprophylaxis after RhD‐negative patients receive RhD‐positive (i.e., RhD‐incompatible) packed red blood cell (pRBC) and platelet transfusions.ResultsApproximately half of the respondents (50.4%, 116/230) have policies on RhIG administration after RhD‐incompatible pRBC and platelet transfusions, while others had policies for only pRBC (13.5%, 31/230) or only platelet (17.8%, 41/230) transfusions, but not both. In contrast, 18.3% (42/230) report that their institution has no written policies on RhIG immunoprophylaxis after RhD‐incompatible transfusions. Most institutions (70.2%, 99/141) do not have policies addressing safety parameters to mitigate the risk of hemolysis associated with the high dose of RhIG required to prevent RhD alloimmunization after RhD‐incompatible pRBC transfusions.DiscussionWith approximately half of US AABB‐accredited institutions report having policies on RhIG immunoprophylaxis after both RhD‐incompatible pRBC and platelet transfusions, some institutions may not be in compliance with AABB standards. Further, most with policies on RhIG immunoprophylaxis after RhD‐incompatible pRBC transfusion do not have written safeguards to mitigate the risk of hemolysis associated with the high dose of RhIG required.ConclusionThis survey underscores the diverse and inadequate institutional policies on RhIG immunoprophylaxis after RhD exposure in Rh‐negative patients via transfusion. This observation identifies an opportunity to improve transfusion safety.
Abstract 1208: Plasma proteomics-based models for predicting therapeutic benefit and immune-related adverse events in non-small cell lung cancer patients treated with immunotherapy
Harel, Michal , Christopoulos, Petros , Koch, Ina , Moskovitz, Mor, Levy‐Barda, Adva , Lotem, Michal, Farrugia, David , Katzenelson, Rivka, Price, Gillian , Cheley, Helen , Hassani, Adam , Abu-Amna, Mahmoud, Geldart, Tom, Chatterjee, Anirban , Polychronis, Andreas, Gottfried, Maya, Lou, Yanyan , Harkovsky, Tatiana, Brewster, A., Wolf, Ido , Tepper, Ella, Yellin, Ben, Sela, Itamar, Elon, Yehonatan, Dicker, Adam P. , Chae, Young Kwang , Sullivan, Ryan J. , Naidoo, Jarushka , Naidoo, Jarushka , Dicker, Adam P , Puzanov, Igor , Bar, Jair , Kamer, Iris , Reinmuth, Niels , Zer Kuch, Alona , Agbarya, Abed , Geldart, Tom, Lahav, Coren , Leibowitz‐Amit, Raya , Carbone, David Paul , Gandara, David R.

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 1208-1208

10.1158/1538-7445.am2024-1208 Get It

Abstract Background: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with metastatic non-small cell lung cancer (NSCLC). However, clinical management is challenging. The PD-L1 biomarker does not optimally guide the choice between ICI monotherapy and combination ICI-chemotherapy, and there are currently no biomarkers to predict immune-related adverse events (irAEs). Here, we describe a versatile platform based on plasma proteomics and machine learning for generating predictive tools to support treatment decisions. Methods: Pre-treatment plasma samples were collected from 616 NSCLC patients receiving ICI-based therapy (NCT04056247). Clinical benefit (CB) data and irAEs were recorded. Proteomic profiling of plasma samples was performed using the SomaScan® assay, covering ~7000 proteins per sample. Proteins associated with Clinical Benefit (progression-free survival at 12 months) were classified as resistance-associated proteins (RAPs). Proteins associated with grade ≥3 irAEs occurring within the first 100 days of treatment were classified as toxicity-associated proteins (TAPs). RAPs and TAPs were integrated into two separate machine learning-based models, yielding CB and irAE probabilities, respectively. The CB model used a CB probability threshold to assign patients a PROphet-positive or PROphet-negative result. Bioinformatic analysis was performed on RAPs and TAPs. Results: CB and irAE models displayed strong predictive performance with a high correlation between predicted probability and observed CB or irAE rate (CB model: R2=0.98; p-value&lt;0.0001; irAE model: R2= 0.92; p-value &lt;0.0001). In the CB model, patients classified as PROphet-positive achieved significantly longer overall survival (OS) than PROphet-negative patients, with a median OS of 25.9 vs. 10.8 months (hazard ratio, HR = 0.51; p-value&lt;0.001). Furthermore, patients with PD-L1 ≥50% tumors and a PROphet-negative result had significantly longer OS with ICI-chemotherapy in comparison to ICI monotherapy (HR=0.23, p-value = 0.0003), suggesting that combination therapy is preferable for such patients despite high PD-L1 levels. Bioinformatic analysis showed that RAPs related to immune regulation, angiogenesis, chemo-resistance, and other potential resistance mechanisms displayed higher expression levels in patients who did not benefit from treatment. Neutrophil- and inflammation-related proteins were significantly enriched in patients who experienced irAEs. Conclusions: We describe two machine-learning based predictive tools that may be used separately or in combination to inform treatment decisions based on the patient’s likelihood to benefit from ICI therapy and to develop serious irAEs. Our findings also provide biological insights related to treatment resistance and immune-related toxicity. Citation Format: Michal Harel, Petros Christopoulos, Igor Puzanov, Jair Bar, Iris Kamer, Niels Reinmuth, Ina Koch, Mor Moskovitz, Adva Levy-Barda, Alona Zer, Michal Lotem, David Farrugia, Rivka Katzenelson, Gillian Price, Abed Agbarya, Helen Cheley, Adam Hassani, Mahmoud Abu-Amna, Tom Geldart, Anirban Chatterjee, Andreas Polychronis, Maya Gottfried, Yanyan Lou, Tatiana Harkovsky, Alison Brewster, Ido Wolf, Ella Tepper, Ben Yellin, Itamar Sela, Coren Lahav, Yehonatan Elon, Raya Leibowitz, Adam P. Dicker, Young Kwang Chae, Ryan J. Sullivan, David Carbone, David Gandara, Jarushka Naidoo. Plasma proteomics-based models for predicting therapeutic benefit and immune-related adverse events in non-small cell lung cancer patients treated with immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1208.
Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer
Christopoulos, Petros , Harel, Michal , McGregor, Kimberly , Brody, Yehuda, Puzanov, Igor , Bar, Jair , Elon, Yehonatan, Sela, Itamar , Yellin, Ben, Lahav, Coren , Raveh, Shani, Farrugia, David , Bustinza-Linares, Ernesto , Lou, Yanyan , Leibowitz‐Amit, Raya , Moskovitz, Mor, Levy‐Barda, Adva , Koch, Ina , Lotem, Michal , Katzenelson, Rivka, Agbarya, Abed , Price, Gillian , Cheley, Helen , Abu-Amna, Mahmoud, Geldart, Tom, Gottfried, Maya, Tepper, Ella, Polychronis, Andreas, Wolf, Ido , Dicker, Adam P. , Gandara, David R. , Reiner-Benaim, Anat , Bustinza-Linares, Ernesto , Lou, Yanyan , Zer Kuch, Alona , Lotem, Michal , Cheley, Helen , Dicker, Adam P , Carbone, David Paul , Gandara, David , Puzanov, Igor , Reinmuth, Niels , Nechushtan, Hovav , Kamer, Iris , Geldart, Tom

Mayo Clinic

JCO Precision Oncology | March 21, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.23.00555 | PMID 38513170 Get It

PURPOSE Current guidelines for the management of metastatic non–small cell lung cancer (NSCLC) without driver mutations recommend checkpoint immunotherapy with PD-1/PD-L1 inhibitors, either alone or in combination with chemotherapy. This approach fails to account for individual patient variability and host immune factors and often results in less-than-ideal outcomes. To address the limitations of the current guidelines, we developed and subsequently blindly validated a machine learning algorithm using pretreatment plasma proteomic profiles for personalized treatment decisions. PATIENTS AND METHODS We conducted a multicenter observational trial (ClinicalTrials.gov identifier: NCT04056247 ) of patients undergoing PD-1/PD-L1 inhibitor–based therapy (n = 540) and an additional patient cohort receiving chemotherapy (n = 85) who consented to pretreatment plasma and clinical data collection. Plasma proteome profiling was performed using SomaScan Assay v4.1. RESULTS Our test demonstrates a strong association between model output and clinical benefit (CB) from PD-1/PD-L1 inhibitor–based treatments, evidenced by high concordance between predicted and observed CB ( R 2 = 0.98, P < .001). The test categorizes patients as either PROphet-positive or PROphet-negative and further stratifies patient outcomes beyond PD-L1 expression levels. The test successfully differentiates between PROphet-negative patients exhibiting high tumor PD-L1 levels (≥50%) who have enhanced overall survival when treated with a combination of immunotherapy and chemotherapy compared with immunotherapy alone (hazard ratio [HR], 0.23 [95% CI, 0.1 to 0.51], P = .0003). By contrast, PROphet-positive patients show comparable outcomes when treated with immunotherapy alone or in combination with chemotherapy (HR, 0.78 [95% CI, 0.42 to 1.44], P = .424). CONCLUSION Plasma proteome–based testing of individual patients, in combination with standard PD-L1 testing, distinguishes patient subsets with distinct differences in outcomes from PD-1/PD-L1 inhibitor–based therapies. These data suggest that this approach can improve the precision of first-line treatment for metastatic NSCLC.
The Relationship between Post-Traumatic Stress Disorder Due to Brain Injury and Glutamate Intake: A Systematic Review
Gruenbaum, Benjamin F. , Matalon, Frederic , Shiyntum, Honore N. , Frenkel, Amit , Boyko, Matthew , Matalon, Frederic , Frenkel, Amit , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich , Oleshko, Anna

Mayo Clinic

Nutrients | March 21, 2024 | Volume: 16 | Issue: 6 | Pages: 901

10.3390/nu16060901 | PMID 38542812 Get It

There is a growing body of evidence that suggests a connection between traumatic brain injury (TBI) and subsequent post-traumatic stress disorder (PTSD). While the exact mechanism is unknown, we hypothesize that chronic glutamate neurotoxicity may play a role. The consumption of dietary glutamate is a modifiable factor influencing glutamate levels in the blood and, therefore, in the brain. In this systematic review, we explored the relationship between dietary glutamate and the development of post-TBI PTSD. Of the 1748 articles identified, 44 met the inclusion criteria for analysis in this review. We observed that individuals from countries with diets traditionally high in glutamate had greater odds of developing PTSD after TBI (odds ratio = 15.2, 95% confidence interval 11.69 to 19.76, p < 0.01). These findings may support the hypothesis that chronically elevated blood glutamate concentrations caused by high dietary intake invoke neurodegeneration processes that could ultimately result in PTSD. Further studies will clarify whether lowering glutamate via diet would be an effective strategy in preventing or treating post-TBI PTSD.